(Q34374135)

1 August 2017

1 reference

title

Review article: the limitations of corticosteroid therapy in Crohn's disease (English)

1 reference

1 August 2017

0 references

Rutgeerts PJ

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Alimentary Pharmacology & Therapeutics

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

1515-1525

1 reference

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Novel therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Management of complications of glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Metabolic bone disease in adults with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Prevention and treatment of osteoporosis in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Use of inhaled corticosteroids and the risk of cataracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Use of infliximab in the treatment of Crohn's disease in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01060.X

10.1046/J.1365-2036.2001.01060.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference